Day: March 31, 2025

Wrap Technologies’ Strategic Reset and Outlook MIAMI, March 31, 2025 (GLOBE NEWSWIRE) — Wrap Technologies, Inc, (NASDAQ: WRAP) (“Wrap” or, the “Company”), a global leader in innovative public safety technologies and non-lethal tools, today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. Q4 2024 Financial Results:Revenue increased 47%, from $0.6 million in 2023 to $0.9 million in 2024. Gross Profit improved by $0.7 million, rising from $(0.3) million in 2023 to $0.4million in 2024 Total Operating Expenses decreased 21%, from $6.3million in 2023 to $5.0million in 2024 Sales, General & Administrative (SG&A) Expenses declined 19%, from $5.8million in 2023 to $4.7million in 2024 Net Loss from Operations improved by $10.8million, decreasing from $(18.4) million in 2023...

Investments in Revitalizing XFC Brand, Producing Three Live Arena Events Highlight First Full Year for New Management, Sports and Entertainment Strategy DETROIT, March 31, 2025 (GLOBE NEWSWIRE) — Xtreme One Entertainment, Inc. (OTCPink: XONI) today announced its financial results for the full year ending December 31, 2024, details of which have been filed within the Company’s annual disclosure statement accessible at https://www.otcmarkets.com/stock/XONI/disclosure. “This past year was one of growth and tremendous development for the team at Xtreme One Entertainment. We came back swinging with three fully produced live events in Florida, Michigan, and Wisconsin that marked the initial success in reinvigorating the storied, but orphaned XFC brand. I’m incredibly proud of the efforts of the entire team and their dedication...

– Grew Total Revenue 8% Year-over-Year to $45 Million in the Fourth Quarter 2024 – – Assets Under Management (“AuM”) Increased 13% Year-over-Year to $27 Billion – – GAAP Net Loss of $1.1 Million in the Fourth Quarter – – Grew Adjusted EBITDA* 43% Year-Over-Year to $2.0 Million in the Fourth Quarter – NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) — Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the quarter and year ended December 31, 2024. “As we celebrate the one-year anniversary of our successful public listing, we’re pleased to deliver our 2024 fourth quarter results,”...

A Series of Milestones, Including Public Listing, Were Achieved in 2024; Longanesi First Gas Production Has Been Achieved Fiscal Year 2024 and Recent Company Highlights:Gas production at Longanesi has commenced as of March 13, 2025 Between March 2024 and July 2024, AleAnna successfully completed three separate strategic acquisitions of renewable natural gas (“RNG”) plant projects in Italy for aggregate consideration of approximately $9.7 million, which generated $1.4 million in electricity production revenue in 2024 On December 13, 2024, AleAnna completed its de-SPAC transaction and became publicly traded on Nasdaq under the ticker symbol “ANNA” AleAnna ended fiscal year 2024 with approximately $28.3 million in cash and cash equivalentsDALLAS, March 31, 2025 (GLOBE NEWSWIRE) — AleAnna, Inc. (“AleAnna” or the “Company”) (NASDAQ:...

Issues guidance following a transformative year with the Company adding two new business lines, significantly strengthening the Balance Sheet and demonstrating enhanced operational capabilities for additional services and consulting related to the fast power business. JACKSONVILLE, Fla., March 31, 2025 (GLOBE NEWSWIRE) — Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT) a provider of machine vision and artificial intelligence that analyzes fast moving vehicles, Edge Data Centers and power solutions, reported financial results for the fourth quarter (“Q4 2024”) and full year ended December 31, 2024.Fourth Quarter 2024 and Recent Operational HighlightsSigned Asset Management Agreement (“AMA”) with New APR Energy and Fortress Investment Group value at up to $42 million to manage 850MW of Gas-Powered Turbines....

LOS ANGELES, March 31, 2025 (GLOBE NEWSWIRE) — Nova LifeStyle, Inc. (NASDAQ: NVFY) (“Nova LifeStyle” or the “Company”) today announced financial results for the fiscal year ended December 31, 2024. Tawny Lam, Chairperson and Chief Executive Officer of Nova LifeStyle, stated, “The Company has substantially changed over the last few years. We have improved our day-to-day operations to ensure we have a long-term strategy in place to weather numerous storms, including the implementation of tariffs, the overall economy and uncertainty in the real estate sector. We are in the process of revamping our product line and will continue to look for new products to complement our existing products. It has been a lot of work to move the Company forward and I want to recognize the dedication of our employees who have embraced these changes to...

TEL-AVIV, Israel, March 31, 2025 (GLOBE NEWSWIRE) — Ellomay Capital Ltd. (NYSE American; TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable energy and power projects in Europe, Israel and USA, today reported the publication in Israel of financial statements for the year ended December 31, 2024 of Dorad Energy Ltd. (“Dorad”), in which Ellomay currently indirectly holds approximately 9.4% through its indirect 50% ownership of Ellomay Luzon Energy Infrastructures Ltd. (formerly U. Dori Energy Infrastructures Ltd.) (“Ellomay Luzon Energy”). On March 31, 2025, Amos Luzon Entrepreneurship and Energy Group Ltd. (the “Luzon Group”), an Israeli public company that currently holds the remaining 50% of Ellomay Luzon Energy, which, in turn, holds 18.75% of Dorad, published its annual...

Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer Biomea preparing icovamenib for late-stage clinical development Multiple milestones anticipated in 2025 including: FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patients COVALENT-111 (T2D) 52-week data anticipated in second half 2025 COVALENT-112 (T1D) open label data anticipated in second half 2025 BMF-650 IND application submission planned in second half 2025REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, reported fourth quarter and full year 2024 financial results and corporate highlights. “2024 was a transformative year for Biomea, marked by the...

Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platformFiled IND in March 2025 for CLD-201 company sponsored Phase 1 trial to treat multiple solid tumors Commencement of recruitment for Phase 1 trial in patients with newly diagnosed high-grade glioma at Northwestern University hospital 14 patients enrolled in Phase 1 trial conducted by City of Hope to treat recurrent high-grade gliomaSAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2024 operating and financial results and reviewed recent business highlights. “Calidi continues to make great progress on...

Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to a 16-point HQ-CT reduction, with an average reduction of approximately 8 points among subjects that followed trial protocol) observed during the 28-day dosing period. DEXA scans analysis from the PWS Phase 2 trial data measuring body composition indicated a trend toward decreased body fat (approximately 1.5%) and increased lean muscle (over 2%) following 28 days of ARD-101 dosing. Ongoing ARD-101 Phase 3 HERO trial to treat hyperphagia associated with PWS is expected to generate topline data in early 2026.  Aardvark bolstered its cash runway through the successful completion of its Initial Public Offering (IPO) in February 2025.SAN DIEGO,...